Summary
This 8-K filing from BeOne Medicines Ltd. (ONC) on December 6, 2018, primarily reports on the presentation of key clinical data at the 60th Annual Meeting of the American Society of Hematology (ASH). Investors should note the presentation of clinical data for zanubrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor, in patients with mantle cell lymphoma (MCL). Additionally, the company presented data for tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with relapsed/refractory classical Hodgkin's lymphoma (cHL). The filing also includes a correction regarding the tislelizumab data, clarifying there were no reported cases of grade 3 productive cough.
Key Highlights
- 1Announcement of clinical data for zanubrutinib in mantle cell lymphoma (MCL) at the 60th ASH Annual Meeting.
- 2Presentation of clinical data for tislelizumab, an anti-PD-1 antibody, in Chinese patients with relapsed/refractory classical Hodgkin's lymphoma (cHL).
- 3Data for both zanubrutinib and tislelizumab were presented at a major hematology conference, indicating progress in their respective clinical development programs.
- 4A press release regarding zanubrutinib was issued on December 1, 2018.
- 5A press release regarding tislelizumab was issued on December 3, 2018.
- 6The filing includes a correction to the tislelizumab press release, specifically addressing an error in reporting adverse events (no grade 3 productive cough cases).
- 7The 8-K incorporates the full text of these press releases as exhibits.